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co.05 vs. baseline). Acetykbolbte also caused a signikant mduction 
in renal vascnlar resistance (maximal reduction 55 + 6%) and 
iucreasebtrenalbloodRow(~lincreasel3fi+:§4%).fn 
contrast, nitmglycertn admbdstration showed no signilicunt e&t on 
tenalvascular&smnceandbloodtlow. 
Concfusions. Stimulation of endotbeliumderived nittic oxide 
witb acetylcboline results ht a significant vasodilatory effect on 
both conductance and resistance renal blood vessels and leads to 
a marked reduction in renal vascular resistance and enhancement 
of renal blood flow. Nitroglycerin, an exogenous nitric oxide 
donor, caused a selective vasodilatoty effect on xual conductance 
but not on resistance blood vessels and failed to increase renal 
blood flow. These data suggest the possibility that stimulation of 
endogenous nitric oxide production in the kidney could be used as 
a therapeutic target for enhancement of renal flow in patients with 
heart failure. 
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O&cfives. This study sought to examine the vasodilatory 
response of the renal circulation to endothelial stimulation in 
patients witb cbronk beurt failure 
Bac&u&. Renal blood flow is often reduced in patients with 
chronic congestive beatt failure and may lead to deterioration of 
remI function. Stimulathm of renal endothelbnu has been shown 
to cause renal vasodilatioo in animals and in isolated human 
renal artery. The vasoregulatory role of the renal endothelium in 
patints with heart failnre has not been evahmted. 
i%fefkd. Renal vasmlUat01~ elka ofendothelial sthmdation with 
acetylcholhtewusassesxdandcomparedwiththatofendothelial- 
iudepedentvclsodilationwlth~~Bothdrogswereinfusod 
intothemahttenalartery.Renalartetycross-sectionalareawus 
measwed witb intmvascular tdtraso~d and renal blood Row vehx- 
ity with the aid of aa intravaswlar Doppler technique 
Renal blood flow is often reduced in patients with chronic 
heart failure (1,2) and may lead to an impairment of renal 
function. Changes in renal blood flow have been commonly 
attributed to central hemodynamic derangement (3). Although 
both cardiac output and regional renal blood flow are often 
reduced in patients with congestive heart failure, the correla- 
tion between these two variables in individual patients has 
been poor (4). In addition, enhancement of cardiac output with 
cardiotonic or vasoactive drugs often results in only a small or 
no effect on renal blood flow (1,5-7). These findings may 
indicate the importance of local mechanisms for vasoregula- 
tion of the renal circulation in patients with congestive heart 
failure. Understanding of such mechanisms may be helpful in 
the design of new therapeutic strategies for improvement of 
renal function in patients with heart failure. 
The role’ of the endothelium as a potent regulator of 
Fmm the Deparhnent of Medicine, Division of Cardiology, University of 
Southern California School of Medicine, Los Angeles, California. 
Mantipt received November 8,199S; revised manuscript received Febm- 
my 9.1996, accepted February 21.1996. 
Address for conesoondenee: Dr. Uri Elkayam, Division of Cardiology, 
University of Southern California School of Medicine, 202.5 Tonal Avenue, Los 
Angeles, California 90033. 
vascular smooth muscle relaxation in various circulatory sys- 
tems has been clearly established in the past several years (&9). 
Recent animal studies have also demonstrated that activation 
of the endothelial L-arginine pathway in isolated kidneys as 
well as in vivo studies can lead to a decrease in renal vascular 
resistance (IO) and an increase in renal blood flow, diuresis 
and natriuresis (11-16). In addition, endothelial ,stimulation 
has been reported to cause relaxation in isolated human renal 
arteries (17). Although these studies support the vasoregula- 
tory role of the renal endothelium, the in vivo effect of 
endothelial stimulation on the renal circulation in humans has 
not been studied. In addition, several investigations have 
demonstrated a significant attenuation of endothelial reaction 
to stimulatory effects in patients with congestive heart failure, 
resulting in impairment of vasodilatory response (l&19). The 
purpose of the present study was, therefore, to evaluate the 
vasodilatoty response of the renal circulation to endothelial 
stimulation in patients with chronic congestive heart failure. 
Methods 
Patients. Twelve male patients in clinically stabie condition 
with a history of moderately severe or severe chronic conges- 
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Figure 1. A, Verification of position of guiding cath- 
eter in the proximal part of the main renal artery by, 
a small amount of contrast medium. 8, Positions of 
the various equipment used for measurements: 1 = 
guiding catheter positioned in the proximal main 
renal artery; 2 = Doppler flow wire: 3 = tip of 
intravascular ultrasound catheter; 4 = fluid-tilled 
catheter in the @lateral renal vein. 
tive heart failure who underwent diagnostic cardiac catheter- 
ization were included in the study (mean age 44 -C 4 years, 
range 26 to 64). The etiology of heart failure was coronary 
artery disease in four patients and unknown in eight. All 
patients had severe depression of left ventricular systolic 
function as documented by contrast or radionuclide ventricu- 
lography or by echocardiography (three patients). Left ventric- 
ular ejection fraction as determined in nine patients ranged 
from 14% to 32% (mean 24 -C 2%). Mean hemodynamic 
values as measure3 during cardiac catheterization were as 
follows: heart rate 86 2 5 beats/min, mean blood pressure 92 + 
4 mm Hg, mean right atrial pressure 8 * 1 mm Hg, mean 
pulmonary artery pressure 31 t 3 mm Hg, mean pulmonary 
artery wedge pressure 20 + 2 mm Hg, cardiac index 3.3 +- 0.2 
liters/min per m’, stroke volume index 39 + 4 ml/min per m* 
and systemic vascular resistance 1,158 x 721 dynesscm-‘. All 
patients signed a consent form approved by the research 
committee of the Los Angeles County/University of Southern 
California Medical Center. 
Study pmtoeol. Organic nitrates (six patients) were discon- 
tinued at least 24 h before the study to prevent attenuation of 
nitroglycerin effect during the study due to nitrate tolerance 
(18); other medications (diuretic drugs in all patients, digoxin 
in 11 and angiotensin-converting enzyme inhibitors in 10) were 
withheld on the day of the study. Premeditation before cardiac 
catheterization included intravenous metoclopramide (10 mg) 
and benadryl(50 mg). During cardiac catheterization and the 
study, patients received 1.0 to 2.0 mg of intravenous midazo- 
lam hyrochloride for sedation. Nitroglycerin, either sublingual, 
intravenous or intracoronary, was not allowed during cardiac 
catheterization and until the end of the study. After comple- 
tion of diagnostic cardiac catheterization, a triple-lumen Swan- 
Ganz catheter used for the performance of right heart cathe- 
terization was withdrawn from the pulmonary artery and 
positioned in the midportion of either the: right or left renal 
vein. In cases where engagement of the Swan-Ganz catheter 
into the renal vein was unsuccessful, a 7F diagnostic Judkins 
right or left coronary artery catheter was used. An 8F angio- 
plasty multipurpose or a Judkins right coronary artery guiding 
catheter was then placed in the ipsilateral renal artery with the 
tip positioned in the proximal or midportion of the main artery 
(Fig. I). Catheter position both in the renal vein and artery was 
confirmed with a small amount (-5 ml) of angiographic 
contrast medium (Hexibrix, Mallinkrodt Medical). A 0.018-in. 
(0.045 cm) Doppler guide wire (Flowire, Cardiometrics, Inc.) 
was then introduced into the guiding catheter through a valved 
sidearm connector, and its tip was positioned under direct 
visualization in the main renal artery and maintained in a 
parallel position to flow. A commercially available 3.5F or 4.3F 
intravascular ultrasound catheter (Mansfield, Boston Scientific 
Corporation) was then placed through the guiding catheter 
and was positioned under fluoroscopic guidance next to the 
Doppler wire (Fig. 1). Images were obtained with a commer- 
cially available intracoronary ultrasound imaging system (Sono 
Intravascular, Hewlett-Packard) at 30 frames/s and recorded 
on 0.5-in. high quality super VHS videotape for subsequent 
off-line analysis. Renal artery lumen planimetry was later 
performed from the taped images, and cross-sectional area was 
determined with specially designed software. The spectral 
Doppler renal blood Row velocities were recorded. The time- 
velocity integral was measured as the area under the outermost 
portion of the spectral velocity envelope. To correct for 
changes related to respiration and cardiac cycle, 15 to 30 beats 
were used for measurements of both renal artery cross- 
sectional area and Doppler velocity time integral, and average 
values are reported. Renal blood flow (in mUmin) was calcu- 
lated as the prodlrct of the cross-sectional area of the renal 
artery and the velocity time integral using the following 
formula: Row = Heart rate per minute x Velocity-time 
integral x Cross-sectional area. Renal blood Row index was 
calculated for each patient by dividing renal blood flow by body 
surface area. Renal vascular resistance was calculated as 
follows: 80 (Mean renal artery blood pressure - Mean renal 
vein pressure) Renal blood flow. 
Renal venous and arterial pressures were measured directly 
with the aid of the venous and arterial catheters, fluid-tilled 
pressure tubings and standard transducers. Infusion of drugs 
was done through the arterial catheter diiectly into the renal 
artery. 
Drugs. Acetylcholine (Miochol, lolab Pharmaceuticals) 
was mixed in 5% dextrose in water to achieve a blood 
concentration of IO-‘, lo-’ and lo-” mobliter, assuming an 
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Table 1. Effects of Acctylcholine and Nitroglycerin on Systemic acl Reudl Hemodjnamic Variables in 12 Patients With Chronic 
Heart Failure - 
Acaylcholinc (mean 5 SE) 
-- Baseline 
Nitrogl+win (mean f SE) 
Bwline IO- ” moC IO-’ IllOIl 10-h ml, (mean f 10 ’ moL 10 ’ molf IV5 mob 
Variable (mean r SE) liter lifer liter ST) liter liter liter 
HR (bea’mii) 89 2 5 8825 9025 90 i 5 117 f 6 89 f 5 nnr.7 9225 
RAP (mm W 9124 88+4 87 2 4 94 _i 4 91 ‘4 9114 95 2 4 x9 + 3 
RVP (mm W IO _+ 1 102 I 1021 II ‘1 1o.r 1 lot I 105 I 10-t I 
QA (mm*) c.37 2 0.03 0.38 t 0.04 0.39 f 0.03 0.40 f 11.03 0.35 2 0.0: 0.37 + 0.03 0.39 2 0.03 0.39 2 0.03 
v-n @) 22 -c 3 3425 42 r 6 45 f 7 24 23 26 f ? 24 + 3 2322 
RBF (ml/min per m’) 289 + 25 497 + 58 652 2 73 b71 i 110 311 z 23 394 -c 38 314 I 38 176 i 32 
RVR (dyness~~~-*) 11,171 + I,?95 6,685 2 124 5.188 f 805 4,868zfa l(J.275 2 931 8.847 I lo60 9,072 c 1,415 x.595 2 x10 
CSA = main renal artery crossseek& area; HR = heart rate; RAP = mean renal artery blood pressure; RBF = renal bled flow: RVP = mean renal vein 
presssure; RVR = renal vascular resistance: WI = velocity-time integral. 
average renal blood flow in patients with chronic heart failure 
of 600 ml/min (4-6). Nitroglycerin (Baxter Healthcare Corpo- 
ration) was infused at a rate calculated to achieve blood 
concentrations of lo-‘, 10e6 and lo-’ mohliter. Both drugs 
were drawn from hospital formuiary stacks and prepared 
<60 min before their use. The drugs were infused at a rate of 
2 ml/mitt controlled by a volumetric pump for approximately 3 
to 5 min for each concentration into the renal artery. Similar 
concentrations of both acetyicholine and nitroglycerin were 
used in previous studies evaluating endotheiiai function of 
coronary and peripheral arterial circulation (19,20). 
istration of acetylcholine and 0.35 t 0.03 cm* before nitrogiyc- 
erin (Table 1); the difference was not statistically significant. 
Both acetylchoiine and nitroglycerin resuhcd in a dose- 
dependent, small but statistically significant, increase in renal 
artery cross-sectional arra (Fig. 2 and 3). Maximal increase in 
this variable was 14 t 5% for acetylchoiine and 15 2 5% for 
nitmzlycerin. The difference between these two interventions 
was not statistically significant. 
Dasehne hemodynamic variables, intravascular ultrasound 
and Doppler flow velocity were measured after 3 to 5 min of 
intraarterial infusion of 5% dextrose in water. After baseline 
measurements, patients were randomized to receive either 
acetylchoiine (six patients) or nitroglycerin infusion (six pa- 
tients) as the first drug. Hemodynamic measurements and 
intravascular uitrasound and Doppler flow velocity recordings 
were repeated during the last minute of infusion of each drug 
concentration. Ten to 15 minutes was then allowed for washout 
of the first drug and was followed by a second baseline 
measurement and the administration of the second drug using 
the identical protocol. 
Velocity-time inregml. There was no significant difference 
between baseline values of the velocity-time integral before 
administration of both drugs (22 -C 3 vs. 24 _’ 3 cm). A 
significant and dose-dependent increase in velocity-time inte- 
gral was found during acetyichoiine infusion (Table 1, Fig. 3). 
The velocity-time integral increased 61 I! 10% during infusion 
of lo-* mot/liter acetylcholine (p < 0.01 vs. baseline) and 
continued to increase during lo-’ and 10m6 mot/liter (99 +- 
15% and 120 + 18%, p < 0.05 vs. lo-* mot/liter for both). In 
contrast, the effect of nitroglycerin on thevelocity-time integral 
was small (Table 1, Fig. 4) and did no+ ac:.ieve statistical 
significance. 
Rend blood flow. As shown in Table 1, there was no 
significant difference between baseline values of renal blood 
Data analysis. An analysis of variance for repeated mea- 
surements was used to determine a statistical difference be- 
tween the absolute values as well as percent differences from 
baseline. In case of a difference, the Newman-Keuls test was 
applied. Data were analyzed for the entire group of 12 
patients. To detect any carry over effect related to the cross- 
over design of the study (21), the same analysis was performed 
for the two subgroups of six patients who received either 
acetyicholme or nitrogtycerin as their first drug., AU results are 
expressed as mean value + SE, a p value ~0.05 was considered 
statistically significant. 
Fwrp 2. Percent change in renal artery cross-sectional area with 
gadded doses of acetylcholine (ACH) and nitroglycerin (NTG) ia 12 
pat&s with heart failure. BL = baseline. 
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I I  
l 
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Results F m- 
Data gmttp analysis for ail 12 patients studied. Renal l ACH 1O4M lo-‘1 lo* M 
artery cross-sectional atea. The ,main renal artery cross- + NT0 to-’ Y loaM lo= Y 
sectional area was 0.37 2 0.03 cm2 at baseline before admin- l pco.asvseL 
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Fire 3. Renal artery cross-sectional area (top) 
and fkppler flow velocity (m/s) (bottom) at base- 
line and during infusion of graded doses of acetyl- 
choline into the renal artery in one of the study 
patients. Reported values of cross-sectional area 
are average of 15 to 30 heats. 
flow as measured before administration of both acetylcholine 
and nitroglycerin (289 2 25 vs. 311 2 23 mUmin per m’). A 
significant and dose-related increase in cakulated renal blood 
flow was found during acetylcholine infusion (Fig. 5). Rena1 
blood flow increased 67 2 12% during 10V8 mobliter acetyl- 
choline (p < 0.05 vs. baseline), 122 2 17% during 10e7 mohliter 
acetykholine and 145 It 1% during 10e6 mol/liter acetykholii 
(both p < 0.05 vs. 10e8 mol/hter). In contrast to the signihcant 
effect of acetykholme on renal blood Raw, intraarterial infusion 
of nitroglycerin at all three doses (Fig. 5) demonstrated ouly a 
small and ?&tically insigniticant change in renal blood flow 
(13 ? 6%,16 ? 8% and 16 + 6%, nqectively). 
Heart rate WK.I bioodpmwes. No significant changes were 
noted in values of heart rate and renal arterial and venous 
blood pressures during the intrarenal infusion of both acetyl- 
choline and nitroglycerin (Table 1). 
Renal vascukrr resivrance. Calculated baseline values of 
renal vascular resistance were comparabie (11,171 t !,295 
0.37 cm2 
Fwrt! ,4. Renal arteT cross-sectional area (top) 
and Doppler fkw velocrry (m/s) Nxrttam) at base- 
line and during infusion of graded doses of nitro- 
glycerin into the renal artery in one of the srudy 1 
@tier&. Reported values of cress-sectional area 
are average of 15 to 30 heats. 
dynesscn-’ for acetylcholine, tO,?i5 z 931 dynesscm‘s for 
nitroglycerin) (Table 1) during acetylcholine infusion. Renal 
vascular resistance was reduced 39 t 5% during 10-s mohliter 
acetylcholine, 52 2 7% during 10e7 mohliter acetylcholine and 
55 + 6% during IO-” mohliter acetykholine (all p < 0.05 vs. 
baseline) (Fig 6). In contrast inrrarenal infusii of graded doses 
of nitroglycerin resulted in a small but statistically insignifkant 
decrease (6 t 6%,4 -t 10% and !2 + 6%: respectively). 
S&group analysis. To detect any carry over effect due to 
the crossover design of the study, a separate analysis was 
performed for the two subgroups of six patients, each receiving 
either acetylcholine or nitroglycerin as the first drug. A com- 
parison of baseline systemic and renal hemodynanric values in 
the two subgroups of six patients receiving either acetylcholine 
or nitroglycerin as their first drug demonstrated similar values 
of heart rate, mean renal arterial blood pressure, Doppler 
velocity-time integral, renal blood flow and renal vascular 
resistance. However, mean value of renal artery cross-sectional 
a42 cd OAOCd 
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Fiire 5. Percent change in renal blood Row vith graded doses of 8 +NTG 10-7 M 10.6 M 10-S M 
acetylcholine (ACH) and nitroglycerin (NTG) in 12 patients with heart . p.0.05vsBLandNTG + pcO.OSvsACHlO*M 
failure. EL = baseline. 
F&are 6. Percent change in renal vascular resistance witn graded 
doses of acetylcholine (ACH) and nitroglycerin (NTG) in 12 patients 
with heart failure. BL = hasctine. 
area was larger in the nitroglycerin group (0.40 2 0.0: vs. 
0.28 2 0.04 cm”, p < 0.05). 
Heart rate showed no significant change during the infusion 
of both drugs at all concentrations (Tables 2 and 3). Mean 
renal arterial blood pressure showed a small but statistically 
significant decline during administration of nitroglycerin at 
concentrations of lo-’ mohliter and remained unchanged 
during acx#choline administration. Both drugs resulted in a 
dose-rehted increase in mean renal artery cross-sectiona! area. 
Although increase in absolute values of cross-sectional area 
did not reach statistical significance during acetylcholine ad- 
ministration, a maximal increase in this variable was similar for 
both drugs (20 5 10% for 10W6 mol/liter acetylcholine, 19 t 
10% for lo-’ mot/liter nitroglycerin, p = NS). Renal vascular 
resistance demonstrated a significant decrease during acetyl- 
choline administration that was associated with a marked and 
statistically significant increase in Doppler velocity-time inte- 
gral and calculated renal blood flow. In contrast, these three 
variables showed no significant change during nitroglycerin 
infusion. 
Discussion 
The present study provides to the best of our knowledge a 
first evaluation of the renal circulatory response to endothelial 
stimu!atioo in patients with chronic congestive heart failure. 
The results of the study demonstrate a marked vasodilatory 
effect of acetylcholine, resulting in a significant increase in 
cross-sectional area of the main renal artery and a substantial 
reduction in renal vascular resistance, accompanied by a marked 
augmentation of renal blood flow. These hndings support previ- 
ously pubiiihed reports demonstrating acetylcholine-mediated 
renal vasodilatoty effects in vitro and in viva animal experimen- 
tatiors (lo-1622-Z) and in isolated human renal artery (17). 
The vasodilatory effect of acetylcholine on the renal circu- 
lation is likely to be mediated by endothelial stimulation of 
endogenous nitric oxide production. This mechanism is sup 
ported by a similar relaxing effect of acetylcholine on human 
and animal renal arteries with but not in those without endothe- 
hum (1726) and previously reported inhibition of renal hemody- 
namic effects of acetylcholine with No-monomethyl-L-arginiie, a 
specific nitric oxide inhibitor, in animal experimentations 
(23,24,272@. EndotheIialderived nitric oxide stimulates the en- 
zyme guanylate q&se, which leads to accumulation of cyclic 
guanosine monophosphate in the vascular smooth muscle, which 
results in vasorelaxation (30). Tolins et al. (29) evaluated the role 
of nitric oxide in regulation of renal hemodynamic responses in 
the anesthetized rat in vivo and demonstrated a dose-related 
relation between the hemcdynamic effect of acetylcholiie and 
rates of cyclic guanosine monophosphate excretion, providing 
further evidence for acetykholine-induced endothelial-derived 
nitric oxide synthesis as the mechanism of renal vasodilation. 
Table 2. Ekct of Acetyicholine Given as First Drug in Six Patients 
Baseline 
ACH lo-“ml/liter 
ACH IO-’ m&liter 
HR RAP CSA RBF RVR 
(beat%tin) (mm Hg) (mm’) g; (mUmin per m’j (dyvmm -‘) 
89 f 6 9o-c5 0.28 f 0.04 2625 278 ” 43 10,567 2 1,926 
91 2 7 8927 0.29 2 0.04 38 k 4’ 483 ? 56’ 6,617 I 1,027’ 
93 2 7 8827 0.30 -t 0.04 48 5 6’t 648 + 62’t 4.43s 2 485’ 
ACH W6 m&liter 93 + 7 8828 0.32 k 0.03 47 f 6’t 654 +_ I+*? 4355 2 243’ 
‘p < 0.05 versus baseline. tp < 0.05 vclsas aotycboline (ACH) IO-’ mot/liter. Data presented are mean value 5 SE. Dtber~abbreviatiom as in Table 1. 
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Tabk 3. Effect of Nitroglycerin Given as First Drug in Si Patients 
HR RAF CSA 
(beats/min) mJ w (mm’) 
Baseline 8429 Y3 2 5 u.40 5 0.05 
NFG IO-’ m&her 8s 2 0 92 + 5 0.43 2 0.04’ 
NTG 1Omo mot/liter 85 z 7 97 + 6 0.45 + 0.04 
NTG IO.+ m&liter 9a-cl 89 + 5’ 0.46 z 0.M’ 
.~- 
VII RBF RVR 
(on) (mUmin per III’) b$lessm 5) 
22z4 2% r 24 11.100 r 1J33 
23 z 4 3rd ‘45 9.444. .,A39 
23+2 353 + 41 10,x,1 : LPI? 
21 24 371 + 44 8654 ..?25 
l p < 0.05 versus baseline. Data presented are mean value 2 SE. NFG = nitrqlycerin: other abbrevia~iom as in Table t 
Nitroglycerin is an organic nitrate with potent vasodilatory 
activity. The therapeutic effect of this drug occurs after intra- 
cellular conversion to nitric oxide, which activates the enzyme 
guanylate cyclase, which leads to the production of cyclic 
guanosine monophosphate and vaso&tation (29-32). Despite 
the shared properties of et&helium-derived nitric oxide and 
organic nitrates, the effects of acetykholine and nitroglycerin 
on the renal circu!ation were diEertnt in the present study. 
Whereas the i&renal administration of nitroglycerin resulted 
in a sekctive vasodilatory effect on the main renal artery, it had 
only little and statistically insignificant effect on renal vascular 
resistance and renal blood flow, indicating a selective effect on 
large conductance vessels but lack of effect on small resistance 
blood vessels in the kidney. In contrast, acetylcholine increased 
main renal artery cross-sectional area, combined with a sub- 
stantial effect on renal vascular resistance and renal blood flow, 
demonstrating its vasodilatory efiect on both large conduc- 
tance and smail resistance renal blood vessels. The effect of 
acetjlcholine on resistance blood vessels in the kidney has also 
been reported (33) in animal studies that showed a vasodila- 
tory effect of acetylcholine on renal interlobular arteries as well 
as on tierent and efferent glornerular microvessels. 
The reason for the difference in the effect of acetylcholme, 
a stimulator of endogenous nitric oxide production, and nitro- 
glycerin, an exogenous nitric oxide donor, is not clear. How- 
ever, failure of systemic administration of nitroglycerin to 
augment renal blood flow measured by other methods has 
previously been demonstrated in both animals and humans 
with heart failure (1,5,33). In addition, a similar selective effect 
of nitroglycerin was demonstrated by Selke et al. (34), who 
showed a potent dilation of large, but only minimal effects on 
small, coronary microvesz&. Lack of available sulfhydryl groups 
was suggested as the cause for the heterogenous re+onse of 
coronary microvascular response to nitroglyczrin (35). 
Several investigators have reported impaired endothelium- 
dependent vasodilator function in patients with heart failure 
(l&20,36). Assessment of the coronary as well as the periph- 
eral c&culatory response to acetylcholine administrqtion was 
shown to be diminished. The results of the present study 
clearly indicate a strong endothelial response in the renal 
circulation in patients with chronic heart failure and should 
provide a basis for further evaluation of the therapeutic 
impliitions of renal endothelial stimulation for improvement 
of renal function in patients with chronic congestive heart 
failure. 
Study limitations. The present study was conducted in a 
randomized, crmer manner. Because of patient consider- 
ations, a washout period in between infusion of the t-wo study 
drugs was limited to 10 to 15 min. Although a similar washout 
period has been used in previous studies (21), a carryaer 
effect with at least partial persistence of the therapeutic effect 
of the first drug during the administration of the second can’t 
be ruled out (fig. 3 and 4). For this reason, an additiona; 
analysis of the effect of each of the study drugs in six of the 
patients who received it 61% was performed The results of this 
analysis demonstrated similar results to those obtained in all 12 
patients aad confirmed the validity of the study findings. In 
addition, all patients in the present study were treated with 
standard heart failure therapy, which could have affected 
endoWial function. 
Sumaey. Our study demonstrates a strong renal vasodi- 
latory effect of acetylcholii, which results in a substantial 
decrease in renai vasc&r resistaoce and augmentation of 
renal blood flow. This effect is liiely to be due to the 
stimulate-y effect of acetylcholine on endothelial prod&on of 
endogenous nitric oxide. Intrarenal administratioil of nitro- 
glycerin, an exogenous nitric oxide donor, could not reproduce 
the acetykholine effect. This drug caused a similar dilation of 
the main renal artery but failed to significantly a&t either 
renal vascular resistance or renal blood fiow. These findings 
indite a selective vasodiiatory effect of nitroglycerin, an 
exogenous nitric oxide donor, on renal conductance but not on 
resistance blood vessels. In contrast, stimulation of endotheli- 
urn-derived nitric oxide with aa%ylcholine results in a signifi- 
cant vasodilation of both conductance and resistance vessels. 
The results of the present study therefore raise [‘he possibility 
of renal endothelial stimulation and endogenous nitric oxide 
productian as a potential therapeutic target for enhancement 
of renal flow in patients with chronic congestive heart failure. 
We Umnk the “~1s~ technicians and card- felh of tbz Cardiac C&e- 
a&.&i Laborakuv of the Los Aageks CoumyiUniwrsity of Southern cali- 
fomia Medical Center for their assistance in the pmfwmance of thb study. 
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